Anticancer Potential of Palladium(II) Complexes With Schiff Bases Derived from 4-Aminoacetophenone Against Melanoma In Vitro

Melanoma represents a big challenge for clinical treatment. Besides being the most aggressive and the deadliest form of skin cancer, it is often refractory to commonly used anticancer drugs. Hence, developing new anti-cancer agents is crucial to improve refractory melanoma treatment. Studies using p...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research Vol. 39; no. 12; pp. 6693 - 6699
Main Authors: Sarto, Luís Eduardo, DE Gois, Elba Pereira, DE Andrade, Gabriela Gomes, DE Almeida, Mateus Silveira, Freitas, Jennifer Tavares Jacon, DE Souza Reis Júnior, Antônio, Franco, Lilian Pereira, Torres, Claúdia, DE Almeida, Eduardo Tonon, Gouvêa, Cibele Marli Cação Paiva
Format: Journal Article
Language:English
Published: Greece International Institute of Anticancer Research 01-12-2019
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Melanoma represents a big challenge for clinical treatment. Besides being the most aggressive and the deadliest form of skin cancer, it is often refractory to commonly used anticancer drugs. Hence, developing new anti-cancer agents is crucial to improve refractory melanoma treatment. Studies using palladium(II) complexes have reported antitumor effects on cancer cells. In this study, we aimed to determine the cytotoxic effect of three novel synthesized Pd(II) complexes with Schiff bases derived from 4-aminoacetophenone on the MDA-MB-435 melanoma cell line. Cells were treated with ligand and Pd(II) complexes. Cell viability, morphology and death induction upon treatment were examined. Novel synthesized Pd(II) complexes led to decreased viability of cells. They also induced morphological alterations and cell death, mainly in the C3 complex. The novel synthesized complexes have a significant cytotoxic effect on cell line MDA-MB-435, especially C3 and can be considered as an antitumor agent for further studies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.13884